Dashboard
1
High Management Efficiency with a high ROE of 12.81%
2
Company has very low debt and has enough cash to service the debt requirements
3
Poor long term growth as Operating profit has grown by an annual rate -13.14% of over the last 5 years
4
Flat results in Dec 24
5
With ROE of 5.17%, it has a Very Attractive valuation with a 0.52 Price to Book Value
6
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.82%
0%
-0.82%
6 Months
-3.2%
0%
-3.2%
1 Year
0.83%
0%
0.83%
2 Years
17.48%
0%
17.48%
3 Years
-6.2%
0%
-6.2%
4 Years
-26.67%
0%
-26.67%
5 Years
-4.72%
0%
-4.72%
Dawnrays Pharmaceutical Holdings Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.71%
EBIT Growth (5y)
-13.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.43
Tax Ratio
11.58%
Dividend Payout Ratio
15.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.00%
ROE (avg)
12.81%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.52
EV to EBIT
2.03
EV to EBITDA
1.39
EV to Capital Employed
0.18
EV to Sales
0.31
PEG Ratio
NA
Dividend Yield
3.96%
ROCE (Latest)
8.66%
ROE (Latest)
5.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
1,272.00
1,485.80
-14.39%
Operating Profit (PBDIT) excl Other Income
384.10
566.00
-32.14%
Interest
1.10
0.40
175.00%
Exceptional Items
6.30
8.40
-25.00%
Consolidate Net Profit
356.50
413.80
-13.85%
Operating Profit Margin (Excl OI)
240.40%
329.00%
-8.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -14.39% vs 5.80% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -13.85% vs -3.05% in Dec 2022
About Dawnrays Pharmaceutical Holdings Ltd. 
Dawnrays Pharmaceutical Holdings Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






